Sandy R. Shultz

Sandy R. Shultz

PhD; MSc; BSc (Hons); Postdoctoral Fellowship

Neurologist

Over 20 years of experience

Female📍 Melbourne

About of Sandy R. Shultz

Sandy R. Shultz is a neurologist based in Melbourne, working from Level 6, 99 Commercial Road, VIC 3004. Neurology can be a tough area to deal with, especially when symptoms change or keep coming back. Sandy helps people understand what is happening and what the next steps can look like.


Over time, Sandy has built more than 20 years of experience in brain and nerve conditions. Many patients seen in this kind of clinic have problems like seizures, repeated fainting episodes, memory or thinking changes, and ongoing trouble after a head injury. At times, people also come in after an event like a stroke, or with concerns around nerve and muscle conditions that affect day-to-day strength and movement.


Common reasons for visits include epilepsy and different types of seizures, such as absence seizures or generalised tonic-clonic seizures. Sandy also looks after people dealing with post-traumatic epilepsy after traumatic brain injury or concussion. In some cases, the focus is on recovery and symptom control, and in others it is about making sense of unusual episodes like status epilepticus, where seizures need urgent attention.


There can also be questions about other brain and nervous system issues, including cerebral hypoxia, encephalitis, and conditions that affect how the brain works over the long term. Sandy may help when someone has ongoing pain linked to nerve problems, or when there are concerns related to progressive neurological illnesses. Conditions mentioned in practice include primary lateral sclerosis and amyotrophic lateral sclerosis (ALS, often called Lou Gehrig’s disease), as well as long-term memory loss and other complex neurological presentations.


Sandy’s training includes a PhD, plus an MSc and a Bachelor of Science (Honours) in Psychology. After studying neuroscience, Sandy completed a postdoctoral fellowship at the University of Melbourne in Australia. That research background helps with careful thinking around symptoms, causes, and how tests and treatment plans fit together. There is also an interest in evidence-based care, and Sandy keeps up with new findings as they come through in the field.


If you are dealing with a neurological concern, it can help to talk it through in a calm, practical way. Sandy aims to make appointments feel clear and grounded, so you leave knowing what is being looked at and why.

Education

  • Bachelor of Science (Honours) in Psychology; University of Saskatchewan, Canada; 1999–2003
  • Master of Science (MSc) in Neuroscience; University of Western Ontario, Canada; 2003–2005
  • Doctor of Philosophy (PhD) in Neuroscience; University of Western Ontario, Canada; 2005–2011
  • Postdoctoral Fellowship; University of Melbourne, Australia; 2011–2013

Services & Conditions Treated

ConcussionPost-Traumatic EpilepsyTraumatic Brain InjuryEpilepsySeizuresAbsence SeizureCerebral HypoxiaGeneralized Tonic-Clonic SeizurePrimary Lateral SclerosisToxoplasmosisAbsence of TibiaAmyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)Chronic PainEncephalitisMemory LossPartial Familial EpilepsyStatus EpilepticusStroke

Publications

5 total
Proteinopathies and the Neurodegenerative Aftermath of Stroke: Potential Biomarkers and Treatment Targets.

Stroke • March 27, 2025

Josh Allen, Charlotte Ermine, Runxuan Lin, Geoffrey Cloud, Sandy Shultz, Pablo Casillas Espinosa

Stroke remains a predominant cause of death and long-term disability among adults worldwide. Emerging evidence suggests that proteinopathies, characterized by the aggregation and accumulation of misfolded proteins, may play a significant role in the aftermath of stroke and the progression of neurodegenerative disorders. In this review, we explore preclinical and clinical research on key proteinopathies associated with stroke, including tau, Aβ (amyloid-β), TDP-43 (TAR DNA-binding protein 43), α-synuclein, and UCH-L1 (ubiquitin C-terminal hydrolase-L1). We focus on their potential as biomarkers for recovery management and as novel treatment targets that may enhance neuronal repair and mitigate secondary neurodegeneration. The involvement of these proteinopathies in various aspects of stroke, including neuroinflammation, oxidative stress, neuronal damage, and vascular dysfunction, underscores their potential. However, further investigations are essential to validate the clinical utility of these biomarkers, elucidate the mechanisms connecting proteinopathies to poststroke neurodegeneration, and develop targeted interventions. Identifying specific protein signatures associated with stroke outcomes could facilitate the advancement of precision medicine tailored to individual patient needs, significantly enhancing the quality of life for stroke survivors.

Acute diffuse axonal injury following repeated mild traumatic brain injury in juvenile rats.

Journal Of Neurophysiology • February 10, 2025

Erin Mcdonagh, Eric Eyolfson, Justin Brand, Sandy Shultz, Brian Christie

Mild traumatic brain injuries (mTBIs) are caused by biomechanical forces being transmitted to the brain, causing neuronal connections to be subjected to sheering forces. The injury severity can be affected by a number of factors that include age and sex, however, there remains a paucity of data on how repeated mTBI (r-mTBI) impacts the female brain. In these studies, male and female juvenile rats [postnatal day (PND) 25-26] were administered a total of eight mTBIs over a 2-day period. Following each mTBI, rats were immediately assessed for acute neurological impairment. After eight mTBIs were completed, the Barnes maze was used to assess spatial learning and memory. Axonal injury was assessed using silver stain histological analyses. We found that injured females exhibited less acute neurological impairment than males. Three days after the final r-mTBI, no significant differences were observed in spatial learning and memory, with all animals showing similar times to locate the escape platform on the reversal trial, additionally there was no main effect of sex in the Barnes maze. Silver stain uptake was significantly increased in the optic tract, corpus callosum, and cortex compared with sham animals at seven days postinjury in a sex-specific manner. Females showed significant increase in all three regions following r-mTBI, whereas males only showed a significant increase in staining in the optic tract. Overall, these findings show that females may be more susceptible to axonal damage than males, and that cognitive deficits were not evident in this population following r-mTBI. These results indicate that there may be benefits in examining biomarkers that reflect axonal injury and the therapies that target reducing axonal degradation.NEW & NOTEWORTHY Diffuse axonal injury is a hallmark feature of all severities of traumatic brain injury (TBI) yet, in preclinical mild (m)TBI research no studies have yet investigated axonal damage with silver stain immunohistochemistry in female animals. This is a critical gap in the literature as recent studies suggest that females experience mTBI more frequently than males. We found that repeated mTBI (r-mTBI) caused significant diffuse axonal injury that was more pronounced in females compared with males.

Next-Day Serum Glial Fibrillary Acidic Protein Levels to Aid Diagnosis of Sport-Related Concussion.

Neurology • February 07, 2025

William O'brien, James Hickey, Steven Mutimer, Lauren Evans, Blake Colman, Becca Xie, Lauren Giesler, Brendan Major, Biswadev Mitra, Gershon Spitz, Terence O'brien, Sandy Shultz, Stuart Mcdonald

Objective: Previous studies on sport-related concussion (SRC) may have measured brain injury blood-based biomarker, glial fibrillary acidic protein (GFAP), either before or after its peak, potentially underestimating the diagnostic value. The primary aim of this study was to evaluate the diagnostic performance of serum GFAP at 24 hours post-SRC. Secondary objectives included assessing whether the timing of sample collection relative to an Australian football match (with or without SRC) affected GFAP levels, evaluating if combining GFAP with symptoms improved discrimination of SRC compared with symptoms alone, and determining the diagnostic utility of serum neurofilament light (NfL) levels at 24 hours post-SRC. Methods: In a prospective cohort study, adult male and female Australian football players of the Victorian Amateur Football Association (Melbourne, Australia) with and without SRC had blood sampled around 24 hours postinjury/postmatch. GFAP and NfL levels were quantified using Simoa assays, and area under the curve (AUC) values were calculated for time bins of 16-24 hours, 24-32 hours, and 36-52 hours. Symptom severity at blood collection was assessed using the Sport Concussion Assessment Tool 5 (SCAT). Results: A total of 151 athletes with SRC (median age 22.5 years; 85% male) and 97 controls (median age 24.3 years; 86% male) were sampled at a median of 24.5 hours (interquartile range [IQR] 21.7-28.0; min-max 16-51.5). Time to sample postmatch did not affect GFAP levels in controls; however, higher GFAP levels correlated with shorter time post-SRC (Spearman r = -0.25, 95% CI -0.40 to -0.09). Median GFAP concentrations were 65.9 pg/mL (IQR 49.1-81.3) in controls, and for SRC, 124.6 pg/mL (IQR 86.7-190.7) at 16-24 hours, 94.5 pg/mL (IQR 61.6-163.9) at 24-32 hours, and 59.9 pg/mL (IQR 49.1-94.7) at 36-52 hours. AUC values at 16-24 and 24-32 hours were 0.83 (95% CI 0.76-0.90) and 0.72 (95% CI 0.64-0.80), respectively. Furthermore, combining GFAP with SCAT symptoms at 16-24 hours enhanced discriminatory capability compared with SCAT symptoms alone (AUC increased from 0.91 to 0.97; z = 2.48, p = 0.01). Serum NfL had a limited diagnostic value (AUC ≤0.60). Conclusions: Serum GFAP measured at 16-24 hours following potential or suspected SRC may be a useful objective aid to SRC diagnosis.

Maternal oxytocin administration mitigates nociceptive, social, and epigenetic impairments in adolescent offspring exposed to perinatal trauma.

Neurotherapeutics : The Journal Of The American Society For Experimental NeuroTherapeutics • January 23, 2025

Adverse childhood experiences (ACEs) alter brain development, leading to vulnerability for chronic pain, mental health disorders, and suicidality. These effects often emerge during adolescence. Importantly, ACEs can occur prenatally, including when exposed to in utero intimate partner violence (IPV) or postnatally as maternal neglect. Maternal social support has demonstrated promise in the mitigation of ACE-related deficits. Oxytocin, which has a role in social-bonding and stress regulation, serves as a suitable surrogate for social support in preclinical studies. Therefore, we aimed to explore the effects of oxytocin on alleviating social deficits, nociception, and epigenetic changes resulting from models that aimed to mimic the stress normally induced following exposure to two ACEs: IPV in utero and maternal neglect. During pregnancy, dams were randomly assigned to experience the model of IPV or a sham insult. Following birth, offspring from the IPV group underwent 10 days of maternal separation. Dams received three days of oxytocin therapy while nursing. In adolescence, half of the offspring underwent a plantar surgery to induce pain. Overall, in adolescence, rats exposed to the ACEs exhibited increased nociceptive sensitivity and aberrant social interactions, particularly among males, further suggesting that ACEs can increase an individual's risk for chronic pain. The ACEs changed gene expression related to social behaviour and neuroplasticity. Maternal oxytocin normalized pain, social, and gene changes, while oxytocin levels in offspring correlated with nociceptive sensitivity. Although ACEs have enduring consequences, the outcomes are modifiable, and oxytocin may be a robust and implementable therapeutic capable of attenuating early adversity.

Associations Between Instrumented Mouthguard-Measured Head Acceleration Events and Post-Match Biomarkers of Astroglial and Axonal Injury in Male Amateur Australian Football Players.

Sports Medicine (Auckland, N.Z.) • October 13, 2024

Lauren Evans, William O'brien, Gershon Spitz, Steven Mutimer, Becca Xie, Lauren Giesler, Brendan Major, James Hickey, Spencer S Roberts, Biswadev Mitra, Terence O'brien, Sandy Shultz, Stuart Mcdonald

Background: Advances in instrumented mouthguards (iMGs) allow for accurate quantification of single high-acceleration head impacts and cumulative head acceleration exposure in collision sports. However, relationships between these measures and risk of brain cell injury remain unclear. Objective: The purpose of this study was to quantify measures of non-concussive head impact exposure and assess their association with blood glial fibrillary acidic protein (GFAP), neurofilament light (NfL) and phosphorylated-tau-181 (p-tau-181) levels in male Australian football players. Methods: A total of 31 athletes underwent in-season (24 h post-match) and post-season (> 5 weeks) blood collections and/or wore HITIQ Nexus A9 iMGs measuring peak linear (PLA) and rotational (PRA) acceleration. Match footage was used to verify and code impacts. Blood GFAP, NfL, and p-tau-181 were quantified using Simoa and natural log transformed for analysis. Associations between post-match biomarkers and within match maximum single impact and cumulative PLA/PRA were assessed with linear mixed models. Results: In-season versus post-season elevations were found for GFAP (mean difference 0.14, 95% CI 0.01-0.26, p = 0.033), NfL (mean difference = 0.21, 95% CI 0.09-0.32, p = 0.001) and p-tau-181 (mean difference = 0.49, 95% CI 0.33-0.65, p < 0.001). Post-match GFAP was associated with maximum single impact PLA (B = 0.003, 95% CI 0.0002-0.005, p = 0.036), cumulative PLA (B = 0.001, 95% CI 0.0002-0.002, p = 0.017), cumulative PRA (B = 0.01, 95% CI 0.002-0.02, p = 0.014), and impact number (B = 0.03, 95% CI 0.003-0.05, p = 0.029) within a single match. Change in NfL levels between two-matches correlated with cumulative PLA (r = 0.80, 95% CI 0.38-0.95, p = 0.005), PRA (r = 0.71, 95% CI 0.19-0.92, p = 0.019) and impact number (r = 0.63, 95% CI 0.05-0.89, p = 0.038). Conclusions: Maximum and cumulative head accelerations in Australian football, measured by iMGs, were associated with elevated blood biomarkers of brain injury, highlighting the potential of both technologies for head impact management in collision sports.

Frequently Asked Questions

What services does Dr Sandy R. Shultz offer?
Dr Sandy R. Shultz specialises in neurology and offers care related to concussion, post-traumatic epilepsy, traumatic brain injury, epilepsy and seizures (including absence seizures), cerebral hypoxia, generalized tonic-clonic seizures, primary lateral sclerosis, toxoplasmosis, amyotrophic lateral sclerosis (ALS), chronic pain, encephalitis, memory loss, partial familial epilepsy, status epilepticus, and stroke.
What conditions does she treat?
She treats a range of neurological conditions including epilepsy, seizures (such as absence seizures and generalized seizures), post-traumatic brain injury, concussion, stroke, memory issues, encephalitis, and motor neuron conditions like ALS and primary lateral sclerosis.
Where is the clinic located?
The clinic is located at Level 6, 99 Commercial Road, Melbourne, VIC 3004, Australia.
How do I book an appointment?
Appointments are arranged through the Melbourne clinic. Please contact the practice to set up a consult with Dr Sandy R. Shultz.
What should I expect at a neurology appointment?
During a neurology appointment, the doctor will review your symptoms, medical history and any tests. They may discuss management options for conditions like epilepsy, seizures, stroke or memory concerns, and outline an appropriate plan.
Which languages does Dr Shultz speak?
The profile lists languages as not specified.